Publications | EATG European AIDS Treatment Group Thu, 16 Nov 2017 19:34:07 +0000 en-US hourly 1 OptTEST policy briefs, legal and regulatory database and advocacy tools Sun, 05 Nov 2017 20:26:17 +0000 A number of tools and resources have been developed within the OptTEST by HiE project to optimise HIV testing and linkage to care. They can be found below, organised under five main categories. Several of the tools and materials have been translated into different European languages. These publications and tools were produced with substantial contribution from EATG and its members, thus ensuring solid involvement of the representatives of the communities of people living with and affected by HIV.

Implementing Indicator Condition (IC) Guided Testing

Improving Linkage To HIV Care

Addressing Legal And Regulatory Barriers To Testing

Addressing Stigma

Assessing Cost-Effectiveness Of Testing

Policy briefs:

Scaling up early diagnosis for HIV through expanded implementation of provider-initiated HIV testing: Final OptTEST_expanding provider initiated testing

Scaling up early diagnosis for HIV through diversifying HIV testing approaches beyond clinical settings: FINAL scaling up testing via diversified testing beyond medical settings


ACCESS TO HIGHLY EFFECTIVE HEPATITIS C TREATMENT IN PORTUGAL – A COMMUNITY PERSPECTIVE Fri, 03 Feb 2017 10:48:14 +0000 EATG is pleased to share this new resource: Access to highly effective hepatitis C treatment in Portugal – A Community Perspective. This case study demonstrates how a country with limited resources, negotiating within the existing financial framework, confidential price negotiations and with ambitious objectives, can yield practical results.

The document presents an example of successful community engagement and activism for highly effective hepatitis C treatment, led by the Grupo de Ativistas em Tratamentos (GAT). It summarises the price and reimbursement negotiations in Portugal. Importantly, it also identifies lessons and recommendations that readers may find helpful in advocating in their own countries for universal (or as close as possible) access to these and other life-saving drugs.

The document explores several key components of successful negotiations process in a context of confidential price negotiations, including the need for community empowerment as well as effective multisectoral collaboration across PLHCV, clinicians, hospital administrators, academics, media contacts and decision makers.

The PWG recommends this document and hopes it will prove useful to others who are working for speedy access to state-of-the-art medicines in their own countries.

Click here for the case study: Community advocacy for access to DAA’s in Portugal 12.2016

Click here for the appendix and additional considerations: Access to DAA’s Portugal – appendix

Twenty years of EATG – Anniversary publication 2012 Wed, 16 Nov 2016 16:19:21 +0000 EATG celebrated 20 years of success in the forefront of HIV activism, treatment literacy and advocacy, and political work with this brochure in 2012.

EATG_20 years report

PrEP in Europe Initiative report Mon, 17 Oct 2016 19:09:52 +0000

The PrEP in Europe Initiative (PiEi) is a new initiative, a coalition of European organisations and activists concerned with HIV prevention and specifically with ensuring access to PrEP (pre-exposure prophylaxis) among people at high risk of HIV.

Our mission is threefold: to disseminate up-to-date information on PrEP access in Europe; to influence policy makers and health funders to adopt PrEP in their countries; and to support organisations, groups and individuals advocating for PrEP in their own countries and communities.

It is run by a steering committee of pan-European advocacy organisations including AVAC, NAM/ AIDSMAP, EATG, AIDS Action Europe, the National AIDS Trust and AIDES.

PiEi is in the process of establishing a permanent secretariat and website, and it already has its own social media page on Facebook.

Read the latest report from May 2017 here: PEI Report May 2017

Open letter to the European Commission on the follow-up of the June 2016 EU Council Conclusions Tue, 04 Oct 2016 08:42:20 +0000

On 17 June, 2016, all 28 European Union (EU) Health Ministers agreed on Council Conclusions to address the imbalances in the pharmaceutical systems in the EU and its Member States. In these Conclusions, the Ministers invited the European Commission to undertake a critical review of the impact of current intellectual property (IP) related incentives on biomedical innovation.

Evidence suggests that current levels of excessive IP rights and related monopoly protections do not contribute to genuine needs-driven medical innovation, and delay generic competition. Instead, this contributes to the development of ‘me too’ medicines, anti-competitive behaviours and high prices of new treatments that are not related to the costs of development.

Read the open letter to the follow-up of the June 2016 EU Council Conclusions on “Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States” here: Open letter to EC-Council Conclusions – 13Sept

Open letter to Frans Timmermans concerning EU strategy for HIV, TB and viral hepatitis Tue, 04 Oct 2016 08:40:14 +0000

We are calling for an EU level strategy underpinned by EU member states’ political agreement and a comprehensive European Commission Action Plan as one of the essential tools to achieve these objectives. We firmly believe that the EU will thereby deliver for the well-being of populations, to reduce health inequalities and to strengthen public health systems in Europe.

Read the open letter to VEU Vice President Timmermans here: Letter to Commission Vice-President on the EU policy framework on viral hepatitis HIV tuberculosis

Open letter concerning the 2017 Estonian Presidency of the European Union Tue, 04 Oct 2016 08:36:19 +0000

The region of Eastern Europe and Central Asia (EECA) is home to the fastest growing HIV and HCV epidemics and the highest rates of multi-drug resistant TB (MDR-TB) in the world. According to WHO, 2013 there were 80% more new HIV cases in Europe compared to 20041. UNAIDS considers the EECA as the only region in the world where HIV prevalence continues to grow2. At the same time, in many countries of the European region, rates of MDR-TB3 are alarming. EECA has the world’s highest rates of new TB patients with MDR-TB4, which has become an epidemic on its own, and TB is among one of the leading causes of death of HIV positive people in the region. Moreover, in many countries hepatitis C prevalence nears 80% in people who use drugs5 and the number of related deaths rises yearly.

Please read the open letter to the Prime Minister of Estonia signed by 66 organisations from 34 European countries: CSO letter to Estonia’s PM FINAL

European AIDS Treatment News – EATN – Complete collection Wed, 03 Aug 2016 18:36:18 +0000 EATN front


The EATG published the European AIDS Treatment News (EATN) for 10 years. This “newsletter” disseminated information for expert patients and treatment activists working across Europe. It contained the latest about medicines development, clinical trials and HIV/AIDS related policy. It was phased out and replaced by the current daily or weekly newsletter, and then increasingly by social media. Distributed by fax and email, it was a beacon of hope and information to many.

This invaluable collection of documents from the early days of patient advocacy and HIV/AIDS activism is now available here for you to read, download and analyse.






























































Pages 1-5 from 2001vol10n6

After 2001







EATN Russian edition


EATN French edition







EATN Spanish edition



Webinar 14/12/2015- HIV and Tuberculosis: Current Guidelines and Treatment Developments for HIV/TB Co-Infection Tue, 12 Jul 2016 21:25:53 +0000  

The European AIDS Treatment Group organised a webinar on Monday, Dec. 14, 4 to 5 p.m. CET to discuss the current HIV/TB co-infection epidemic and treatment guidelines as well as the health products pipeline under development.

The webinar intended to provide updated information for community representatives working in HIV/TB treatment advocacy in Europe.

Confirmed Speakers:

Masoud Dara

Senior Advisor of World Health Organization Office at the European Union.

Mike Frick

TB/HIV Project Officer of the Treatment Action Group (TAG).

Wim Vandevelde

EATG member and Chair of the Global Tuberculosis Community Advisory Board (TB-CAB).


The invited Speakers provided information about the current HIV/TB co-infection treatment and the barriers which are still limiting the control of the epidemic. They explained recent research developments in tuberculosis and how the current pipeline looked like, as well as the challenges that HIV/TB advocates can help to overcome.

Slide decks:


TB Drug Pipeline EATG — MFrick

TB-HIV in Europe.DrMasoudDara


Link to audio recording of the webinar


Treatment Advocacy Training Manual – English and Russian versions Sat, 04 Jun 2016 17:40:00 +0000 Treatment Advocacy Training Manual English: Treatment Advocacy EN1

Treatment Advocacy Training Manual Russian: Treatment Advocacy RU1

Treatment Literacy Training Manual – English and Russian versions Sat, 04 Jun 2016 17:35:20 +0000 Treatment Literacy Training Manual English: Treatment Literacy EN

Treatment Literacy Training Manual Russian: Treatment Literacy RU

Clinical Trial Sites across Eastern Europe and Central Asia Sat, 04 Jun 2016 09:29:22 +0000 Clinical trials and studies remain an important vehicle for some to access life-saving medication. In an attempt to make sure that pharmaceutical companies and CROs can diversify the list of trial sites and centres they use, ECAB commissioned, in December 2015, a research into possible centres where sufficient capacities, personnel and patients are available for the organisation of clinical studies.

Clinical Trial Sites in Eastern Europe and Central Asia HIV, HCV, TB – Brief Landscape Review: eeca_clinical_trial_sites_report_for_dissemination

Accredited clinical trial sites in Russia: List_of_accredited_clinical_trial_centres_infectious_diseases_Russia_ru

Accredited clinical trial sites in Ukraine: list_of_clinical_trial_sites_Ukraine_2015_quarter_3

ECAB Review Paper and Brochure Sat, 04 Jun 2016 08:39:21 +0000 In 2013-2014 ECAB performed a thorough review of its history and processes, and performed a scientific analysis of how ECAB has been a novel and unique vehicle for knowledge production in the cross-section of academia, the pharmaceutical industry, regulators and the civil society. The following documents have been produced in the course of the ECAB Review.

ECAB Review Summary Brochure: The impatient patient

Full Scientific Paper “The Impatient Patient”: bereczky-5-2

Conference Poster: 02_EATG_revPoster

Webinar – Affordability and Access to Medicines Fri, 03 Jun 2016 19:13:04 +0000 This webinar on the basics of affordability of and access to medicines is somewhat focused on Eastern Europe though it is relevant to other parts of Europe, too.  It addresses the IP international framework and some of the underused ways around it to ensure access to affordable state of the art medicines for HIV, TB and HCV. It contains a discussion on voluntary licensing (e.g. through the Medicines Patent Pool, limits, improvements and red lines towards industry), and the underused possibilities of compulsory licensing (also including for prevention). There is also some discussion on the challenges of TRIPS + provisions and the problems brought by the Deep Free Trade Agreements to Moldova, Ukraine and Georgia in terms of hindering access to cheaper quality medicines.

The presentations can also  be viewed here:

Boyan Konstantinov:

Esteban Burrone:




EATG + AVAC Prevention Summit 1 Report Fri, 03 Jun 2016 18:46:16 +0000 New Developments in HIV Prevention Meeting Report 2015


STEPS – A community initiative to design the pathway to a long-term remission of HIV infection – Report Fri, 03 Jun 2016 18:24:55 +0000 STEPS 2015 Workshop_Report

Sitges Meeting VI Report Fri, 03 Jun 2016 18:11:46 +0000 SITGES VI report

Sitges Meeting VII Report Fri, 03 Jun 2016 18:10:58 +0000 Sitges VII report


EUROCOORD Community Workshop Report and Slides Fri, 03 Jun 2016 18:08:19 +0000 EuroCoord-Worskhop-Report-Nov-2015-FINAL

SP_gender gap


KP_EuroCoord achievements

KP_Cohort basics

BT_November 2015 ECAB-Eurocoord

MP_Eurocoord_EATG joint workshopnovember2015_def

OK_Co-infections – talk 1

KP_EuroCoord application



DB_EATG_Oral presentation

AM_EC_Eurocoord_EATG workshop_Brussels_09 11 15


EATG + AVAC Prevention Summit 2 Report Fri, 03 Jun 2016 17:41:15 +0000 The report from the meeting gives an excellent summary of the entire event with links to the presentations.

Executive Summary Meeting Report Final

The videos shot at the Prevention Summit, produced and edited by prevention champion Nick Feustel make advocacy and science results even more accessible:

Prevention Summit 2016 (1/3): PrEP from georgetown media on Vimeo.


SITGES VIII MEETING Access to HCV Treatment in Europe 53 All Inclusive? Thu, 21 Jan 2016 16:47:09 +0000 Sitges VIII Meeting_FINAL_18.12

Access to HCV Treatment in Europe – presentation